Hosted on MSN4h
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Genentech announces INAVO120 study met key secondary endpoint
Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...
pharmaphorum2d
Genentech extends small-molecule R&D with three platform deals
Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...
FierceBiotech18h
Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...
EuropaWire1d
Roche Reports Sustained Two-Year Improvements with Elevidys Gene Therapy for Duchenne Muscular Dystrophy
Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approv ...